Luzhu Bio-B (02480) announced interim results, net loss of 61.622 million yuan, a year-on-year decrease of 20.6%

According to the Zhitong Finance App, Luzhu Bio-B (02480) announced its 2026 interim results. Other revenue was 6.762 million yuan, up 39.4% year on year; R&D expenses were 303.31 million yuan, down 39.7% year on year; net loss was 61.62 million yuan, down 20.6% year on year; loss per share was 0.31 yuan.

According to the announcement, the increase in other revenue was mainly due to an increase in government subsidies and rental revenue, which was partially offset by a decrease in interest income and sales revenue of immunoassay kits.

The decrease in R&D expenses is mainly due to the fact that R&D expenses are related to the progress of R&D pipelines. Since most pipeline varieties are in the pre-clinical stage, R&D expenses are low.